Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: Randomized placebo-controlled trial

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 23

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

339

HTML

2884

Figures (1-4)

281

Tables (1-2)

225

Sum=3729

Jun 21, 2007 (publication date) through Feb 18, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Liver Cancer

World J Gastroenterol. Jun 21, 2007; 13(23): 3164-3170
Published online Jun 21, 2007. doi: 10.3748/wjg.v13.i23.3164

Table 2 Follow up of patients

	SSTR-negativegroup	Controlgroup	Octreotidegroup	P
Number of events within 6 mo	25 (38%)	12 (40%)	6 (13%)	0.171
Number of events within 12 mo	65 (99%)	29 (97%)	21 (70%)	< 0.001
Number of events at the end of follow up	66 (100%)	30 (100%)	29 (97%)	1.000
Overall survival time (wk)	28; 21 to 33	28; 19 to 34	49; 28 to 72	< 0.0001

Citation: Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Panagiotakos D, Fotopoulou A, Chrysohoou C, Bazinis A, Daskalopoulou D, Paraskevas E. Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: Randomized placebo-controlled trial. World J Gastroenterol 2007; 13(23): 3164-3170
URL: https://www.wjgnet.com/1007-9327/full/v13/i23/3164.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i23.3164